For research use only. Not for use in humans.

Alirocumab (anti-PCSK9)

Synonyms: NARC-1, neural apoptosis regulated convertase 1

Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Alirocumab (anti-PCSK9)

Click to purchase the isotype control of Alirocumab (anti-PCSK9)

Quality Control

Batch: A204701 Purity: 98% Protein concentration: 4.3mg/ml Endotoxin Level: <1 EU/mg
98

Specificity

Name Citation PCSK9
PF-06446846 0
PF-06446846 hydrochloride 0
SBC-110736 0
R-IMPP 0
SBC-115076 9
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

Product Details

CAS No. 1245916-14-6
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Alirocumab (anti-PCSK9)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07586540 NOT_YET_RECRUITING Drug: Alirocumab|Drug: Placebo|Drug: Atorvastatin Carotid Stenosis Middle East North Africa Stroke and Interventional Neurotherapies Organization 2027-07 PHASE3
NCT07686796 NOT_YET_RECRUITING Drug: CAPOX (oxaliplatin/capecitabine)|Drug: Sintilimab|Drug Local Advanced Rectal Cancer; PD-1 Inhibitor; PCSK9 Inhibitor; RCT; Radiotherapy; Capecitabine; Oxaliplatin Guangdong Provincial People's Hospital 2027-01-01 PHASE3
NCT06385262 SUSPENDED Drug: Alirocumab|Drug: Cemiplimab|Drug: Chemotherapy Non Small Cell Lung Cancer Duke University 2025-03-17 PHASE2
NCT07704918 RECRUITING Drug: Statins (atorvastatin, rosuvastatin, simvastatin, or p Melanoma University of Colorado, Denver 2026-12-31
NCT07581808 RECRUITING Drug: Inclisiran|Drug: Alirocumab Hypercholesterolemia; Atherosclerotic Cardiovascular Disease (ASCVD) University Medical Centre Ljubljana 2026-05-18 PHASE4
NCT04781322 RECRUITING Drug: Alirocumab Alcohol Associated Liver Disease; Heavy Drinking Behavior National Institute on Alcohol Abuse and Alcoholism (NIAAA) 2021-10-19 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-05-14)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.